Results 51 to 60 of about 4,350 (187)

Cutaneous lupus erythematosus: An update

Indian Dermatology Online Journal, 2014
Lupus erythematosus (LE) is a chronic, autoimmune, multisystem disease that displays many diverse symptoms in which localized cutaneous LE (CLE) is on one end of the spectrum and severe systemic LE (SLE) on the other end.
Carina M Grönhagen, Filippa Nyberg
doaj   +1 more source

Epidermal Interferon‐κ Drives Cutaneous Lupus‐Like Lesions, Photosensitivity, and Systemic Autoimmunity In Vivo

Arthritis &Rheumatology, Volume 78, Issue 1, Page 184-197, January 2026.
Objective Keratinocyte‐derived interferon (IFN) κ is chronically overexpressed in human nonlesional systemic lupus erythematosus (SLE) skin. Recent evidence suggests that epidermal signals instruct the immune system in SLE, but whether epidermal IFNκ alone is sufficient to drive lupus phenotypes has not been investigated.
Benjamin Klein, Deborah J. Colesa, Yiqing Gao, Patrick A. O'Brien, Lin Zhang, Lori Lowe, Kelsey E. McNeely, Nguyen Thi Kim Nguyen, Svenja Henning, Mehrnaz Gharaee‐Kermani, Jeffrey B. Hodgin, Jacob W. S. Martens, Johann E. Gudjonsson, Celine C. Berthier, J. Michelle Kahlenberg   +14 more
wiley   +1 more source

Energy‐Based Devices for the Treatment of Cutaneous Lesions in Patients With Lupus Erythematosus and Dermatomyositis

Journal of Cosmetic Dermatology, Volume 25, Issue 1, January 2026.
ABSTRACT Background The use of energy‐based devices (EBDs) for aesthetic and dermatological conditions is increasing, but data on efficacy and safety in autoimmune connective tissue disease (CTD) patients remain limited. Objectives This study assesses EBD real‐world treatment outcomes in Korean patients with lupus erythematosus (LE) and dermatomyositis
Hae Chang Joh, Mihn‐Sook Jue, Joo Yeon Ko   +2 more
wiley   +1 more source

Orchestration of Skin Pathology in Cutaneous Lupus Erythematosus by HLA Class I Down‐Regulated Senescent Epidermal Basal Cells

Arthritis &Rheumatology, Volume 77, Issue 12, Page 1713-1725, December 2025.
Objective This study investigates the role of senescent epidermal basal cells in cutaneous lupus erythematosus (CLE) pathogenesis using skin samples from patients with CLE and a mouse model of systemic lupus erythematosus (SLE). Methods Cellular senescence profiling used datasets from the NCBI GEO database and Accelerating Medicines Partnership (AMP ...
Sena Yamamoto, Yuki Saito, Tsukasa Sato, Seina Nakano, Dain Kasseki, Ayaka Nagao, Norihiro Miura, Kentaro Nagaoka, Arisa Kita, Maki Miyajima, Shogo Ijima, Koji Taniguchi, Atsushi Niida, Takako S. Chikenji   +13 more
wiley   +1 more source

Ro60 and La ribonucleoproteins become self-aggregated by cell stress

Reumatismo, 2011
Ro is a cellular particle composed by three ribonucleoproteins of 60, 54 and 52 kDa (1-3). Ro60 forms a complex with one of the 1-5 hYRNAs (4). Antigenic properties of Ro were described by Clark in 1969 using autoimmune sera (5), and it is broadly ...
E. Avalos-Díaz, D. Herrera-van-Oostdam, S.H. Sánchez-Rodríguez, R. Herrera-Esparza   +3 more
doaj   +1 more source

Golimumab-Exacerbated Subacute Cutaneous Lupus Erythematosus [PDF]

Archives of Dermatology, 2012
Subacute cutaneous lupus erythematosus (SCLE) is characterized by annular, nonscarring, photodistributed, or papulosquamous lesions. The disease may be idiopathic, drug induced, or drug exacerbated.A 66-year-old woman with a history of hypertension, parkinsonism, rheumatoid arthritis, anxiety and depression, and symptoms of Sjögren syndrome was seen ...
Eric, Wilkerson, Matthew A, Hazey, Soon, Bahrami, Jeffrey P, Callen   +3 more
openaire   +2 more sources

Pharmacodynamic Effects of Litifilimab in Lupus in a Randomized, Placebo‐Controlled Phase 2 Study: Rapid and Sustained Reductions in Type I Interferon‐Associated Gene Expression and Cytokines

Arthritis &Rheumatology, Volume 77, Issue 12, Page 1726-1738, December 2025.
Objective The pharmacodynamic effects of litifilimab on type I interferon (IFN) response and correlations with clinical outcomes were investigated in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Methods Participants from part A (SLE) or part B (CLE with or without SLE) of the randomized phase 2 LILAC trial who received ...
Richard Furie, Victoria P. Werth, Eric Milliman, Kyle Ferber, Roland Brown, Jad Zoghbi, Nathalie Franchimont, Youmna Lahoud, Catherine Barbey   +8 more
wiley   +1 more source

The Evolving Landscape of Immunotoxicity: Charting Mechanisms and Future Strategies for Immune Checkpoint Inhibitor Adverse Events

Med Research, Volume 1, Issue 3, Page 322-358, December 2025.
ABSTRACT The use of immune checkpoint inhibitors (ICIs) has significantly improved the efficacy of cancer therapy, but their associated immune‐related adverse events (irAEs) can severely compromise treatment safety. This review systematically summarizes the core mechanisms underlying irAEs, which include multi‐organ damage resulting from T‐cell ...
Anqi Lin, Keyin Zheng, Aimin Jiang, Xufeng Huang, Qi Wang, András Hajdu, Zhengrui Li, Jian Zhang, Peng Luo   +8 more
wiley   +1 more source

SCLE-LP overlap syndrome

Indian Journal of Dermatology, 2011
A 35-year-old female presented with scaly annular and pigmented lesions all over the body of 2 years duration. Her clinical features, histopathology, immunofluorescence findings and positive ANA and anti-Ro antibodies were suggestive of subacute ...
C Shanmuga Sekar, Reena Rai, N Karthika, A Laila   +3 more
doaj   +1 more source

Immunity Switches and Macrophage Manipulations: Trauma, Ovulation, and Depression as Latent Tuberculosis Reactivation Risks

American Journal of Human Biology, Volume 37, Issue 9, September 2025.
ABSTRACT Inflammation is the immune system's natural response to initial tuberculosis infection. Tuberculosis bacteria have gained adaptations to manipulate the inflammatory process, sometimes settling into latency and containment in granulomas, ensuring their survival.
Stacie Burke
wiley   +1 more source